

SLx-2119

Catalog No: tcsc0776



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

911417-87-3

Formula:

$C_{26}H_{24}N_6O_2$

Pathway:

TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage

Target:

ROCK;ROCK;ROCK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 29 mg/mL (64.09 mM)

Alternative Names:

ROCK inhibitor;KD-025

Observed Molecular Weight:

452.51


Product Description

SLx-2119 is a selective inhibitor of **ROCK2** with **IC₅₀** of 105 nM, more than 200 fold selectivity over ROCK1 (IC₅₀=24 μM).

IC50 & Target: IC50: 105 nM (ROCK2)^[1]

In Vitro: SLx-2119 (40 μM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays^[1].

In Vivo: KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!